Download PDF
CC BY 4.0 · Surg J (N Y) 2022; 08(03): e174-e178
DOI: 10.1055/s-0042-1744152
Case Report

Primary Cervical Carcinosarcoma: Report of a Rare Case

Georgios Tsatsaris 
1   Department of Obstetrics and Gynecology, Democritus University of Thrace, Dragana, Alexandroupolis, Greece
,
Zacharias Fasoulakis
2   Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, General Hospital of Athens “ALEXANDRA,” Athens, Greece
,
Antonios Koutras
2   Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, General Hospital of Athens “ALEXANDRA,” Athens, Greece
,
Thomas Ntounis
2   Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, General Hospital of Athens “ALEXANDRA,” Athens, Greece
,
Athina A. Samara
3   Department of Surgery, University Hospital of Larissa, Larissa, Greece
,
Athanasios Syllaios
4   Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
,
Alexandros Diamantis
3   Department of Surgery, University Hospital of Larissa, Larissa, Greece
,
Maria Kouroupi
5   Department of Pathology, Democritus University of Thrace, Dragana, Alexandroupolis, Greece
,
Charilaos Stamos
5   Department of Pathology, Democritus University of Thrace, Dragana, Alexandroupolis, Greece
,
Emmanuel N. Kontomanolis
1   Department of Obstetrics and Gynecology, Democritus University of Thrace, Dragana, Alexandroupolis, Greece
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Background Carcinosarcomas are malignant mixed Müllerian tumors (MMMT), containing both epithelial and mesenchymal components. Carcinosarcomas of the uterine cervix comprise an extremely rare histopathological entity, with less than 150 cases reported in the literature to date.

Materials and Methods A 79-year-old postmenopausal female patient was referred to our gynecological department due to a pelvic mass and vaginal bleeding. A cervical curettage was performed and the histological report revealed a malignant neoplasm with high cellularity consisting of two components; the first was a chondrosarcoma and the latter a adenocarcinoma. A diagnosis of MMMT was confirmed through immunohistochemical (IHC) staining. Neoadjuvant chemotherapy and radiotherapy were implemented, and a year later the patient underwent a radical hysterectomy and oncological pelvic lymph node dissection. She remains disease-free 12 months postoperatively.

Conclusion Primary cervical carcinosarcomas are extremely rare tumors demonstrating a bipartite profile. Preoperative diagnosis with appropriate immunochemistry testing of this rare entity is crucial to decision making.

Keywords

carcinosarcoma - cervical cancer - malignant mixed Müllerian tumors

Authors' Contributions

G.T., A.K., Z.F., A.A.S., T.N., A.D., and E.N.K. contributed to conception and design. A.K., E.N.K., and A.S. were responsible for overall supervision. A.K., M.K., A.A.S., and G.T. drafted the manuscript, which was revised by E.N.K. All authors read and approved the final manuscript.




Publication History

Received: 26 December 2021

Accepted: 31 January 2022

Article published online:
02 August 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol 2011; 23 (05) 531-536
    CrossrefPubMedGoogle Scholar
  • 2 Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet 2018; 143 (suppl 2): 51-58
    CrossrefPubMedGoogle Scholar
  • 3 Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed Müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int 2011; 2011: 470795
    CrossrefPubMedGoogle Scholar
  • 4 Wells M, Oliva E, Palacios J, Prat J. Mixed epithelial and mesenchymal tumors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO Classification of Tumours of Female Reproductive Organs. Lyon: International Agency for Research on Cancer; 2014: 151-152
    Google Scholar
  • 5 Grayson W, Taylor LF, Cooper K. Carcinosarcoma of the uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol 2001; 25 (03) 338-347
    CrossrefPubMedGoogle Scholar
  • 6 de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol 2011; 24 (10) 1368-1379
    CrossrefPubMedGoogle Scholar
  • 7 Singh R. Review literature on uterine carcinosarcoma. J Cancer Res Ther 2014; 10 (03) 461-468
    CrossrefPubMedGoogle Scholar
  • 8 Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998; 29 (01) 82-87
    CrossrefPubMedGoogle Scholar
  • 9 Cherniack AD, Shen H, Walter V. et al; Cancer Genome Atlas Research Network. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 2017; 31 (03) 411-423
    CrossrefPubMedGoogle Scholar
  • 10 Varela-Duran J, Nochomovitz LE, Prem KA, Dehner LP. Postirradiation mixed Müllerian tumors of the uterus: a comparative clinicopathologic study. Cancer 1980; 45 (07) 1625-1631
    CrossrefPubMedGoogle Scholar
  • 11 Kimyon Comert G, Turkmen O, Karalok A, Basaran D, Bulbul D, Turan T. Therapy modalities, prognostic factors, and outcome of the primary cervical carcinosarcoma: meta-analysis of extremely rare tumor of cervix. Int J Gynecol Cancer 2017; 27 (09) 1957-1969
    CrossrefPubMedGoogle Scholar
  • 12 Homesley HD, Filiaci V, Markman M. et al; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25 (05) 526-531
    CrossrefPubMedGoogle Scholar
  • 13 Galaal K, van der Heijden E, Godfrey K. et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013; 2013 (02) CD006812
    PubMedGoogle Scholar
  • 14 Vordermark D, Medenwald D, Izaguirre V, Sieker F, Marnitz S. The role of postoperative radiotherapy for carcinosarcoma of the uterus. Cancers (Basel) 2020; 12 (12) 3573
    CrossrefPubMedGoogle Scholar
  • 15 Wilkinson-Ryan I, Frolova AI, Liu J. et al. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int J Gynecol Cancer 2015; 25 (01) 63-68
    CrossrefPubMedGoogle Scholar
  • 16 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386 (9990): 249-257
    CrossrefPubMedGoogle Scholar
  • 17 Matsuo K, Johnson MS, Im DD. et al. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol 2018; 117 (03) 488-496
    CrossrefPubMedGoogle Scholar
  • 18 Wolfson AH, Wolfson DJ, Sittler SY. et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994; 52 (01) 56-62
    CrossrefPubMedGoogle Scholar
  • 19 Amant F, Cadron I, Fuso L. et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005; 98 (02) 274-280
    CrossrefPubMedGoogle Scholar